The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
The high incidence of vascular thromboembolic events (VTE) in advanced urothelial cancer (UC) patients (pts) treated with carboplatin (Cb): Analysis of treatment with gemcitabine (G)/cb (GCb), gcb/bevacizumab (GCbBev), or gemcitabine/cisplatin (GCis).
Christopher Michael Tully
No relevant relationships to disclose
Andrea Borghese Apolo
No relevant relationships to disclose
Emily C. Zabor
No relevant relationships to disclose
Ashley Marie Regazzi
No relevant relationships to disclose
Irina Ostrovnaya
No relevant relationships to disclose
Jonathan E. Rosenberg
No relevant relationships to disclose
Dean F. Bajorin
Consultant or Advisory Role - Bristol-Myers Squibb; Lilly
Honoraria - Lilly